Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
– Preclinical data suggest combination of ziftomenib and imatinib has potential to resensitize patients to imatinib and induce durable responses –
Kura Oncology to Report Second Quarter 2024 Financial Results
07:30am, Thursday, 01'st Aug 2024
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Don't Miss Out: 3 Stocks Poised for a 10X Surge
07:01am, Friday, 26'th Jul 2024
The first lesson in investing is that returns are not guaranteed — especially in stocks. Companies constantly fluctuate in value as the wheel of the stock market turns, and daily trades come in by t
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 05'th Jul 2024
SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
07:30am, Monday, 24'th Jun 2024
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes –
Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community
02:00pm, Tuesday, 11'th Jun 2024
SAN DIEGO--(BUSINESS WIRE)--Life Science Cares San Diego, a nonprofit organization activating the financial and human capital of the life sciences industry and partnering with local nonprofits to disr
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 07'th Jun 2024
SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine
Kura Oncology to Participate in Jefferies Global Healthcare Conference
07:30am, Wednesday, 29'th May 2024
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
07:30am, Tuesday, 14'th May 2024
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA
2 Incredible Growth Stocks to Buy Hand Over Fist
08:30am, Wednesday, 08'th May 2024
Growth stocks are experiencing a multi-decade bull run at the moment. Kura Oncology and Hims & Hers are two red-hot growth stocks worth checking out right now.
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
07:30am, Wednesday, 08'th May 2024
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o
Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript
05:28pm, Saturday, 04'th May 2024
Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Pete De Spain - EVP, IR Troy Wilson - President & CEO Thomas Doyle - SVP of Finance & Ac
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 03'rd May 2024
SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines
Kura Oncology Reports First Quarter 2024 Financial Results
04:05pm, Thursday, 02'nd May 2024
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive
Kura Oncology to Report First Quarter 2024 Financial Results
07:30am, Thursday, 25'th Apr 2024
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
